thrombosis and thromboembolism phần 4

Đối với những cá nhân này, các numberneeded điều trị cũng rất thấp (NNT 48). Ngược lại, lovastatin dường như không có hiệu lực trong những người tham gia trong AFCAPS / TexCAPS những người có mức LDL dưới mức trung bình và dưới trung bình | Low-Molecular-Weight Heparins 99 Trials in Cardiovascular Disease. Philadelphia . Saunders Company 1999 145-165. 70. Neuhaus KL von Essen R Tebbe U et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis HIT-III study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte AlKk see comments . Circulation 1994 90 1638-1642. 71. Neuhaus KL Molhoek GP Zeymer U et al. Recombinant hirudin lepirudin for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction results of the HIT-4 trial. J Am Coll Cardiol 1999 34 966-973. 6 Platelet Glycoprotein IIb IIIa Inhibition in Acute Coronary Syndromes Christopher P. Cannon Brigham and Women s Hospital and Harvard Medical School Boston Massachusetts Because approximately 4 million patients each year are admitted to hospitals worldwide with unstable angina or acute myocardial infarction MI and nearly 1 million patients annually worldwide undergo percutaneous coronary intervention PCI physicians have focused a great deal of attention on developing new treatments for these acute coronary syndromes ACS . The initiating event of these acute coronary syndromes is rupture of an atherosclerotic plaque followed by local thrombosis. Similar pathophysiology is present during PCI which is essentially a planned plaque disruption. Antiplatelet therapy is the cornerstone of treatment in ACS. Aspirin has been shown to have dramatic effects in reducing both mortality and nonfatal events in patients across the spectrum of acute coronary syndromes 1-8 . In addition the newer agents clopidogrel and ticlopidine have been shown to be beneficial in reducing clinical events compared with aspirin alone in coronary stenting 9-13 and in symptomatic patients with atherosclerosis 1 14 15 . The newest class of drugs is the platelet glycoprotein GP IIb IIIa receptor inhibitor group of agents which